Navigation Links
Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction

RYE, N.Y., Aug. 9, 2013 /PRNewswire/ -- Curemark, a drug research and development company focused on neurological disorders, announced that the company has been awarded a new patent for its proprietary technology CM-1212 for the treatment of individuals with drug and alcohol addiction.  The new patent, #8,486,390, is entitled "Pharmaceutical Preparation for the Treatment of the Symptoms of Addiction and Methods of Diagnosing the Same."  It is the third in a series of patent grants for this indication.

"Physiological symptoms of drug and alcohol addiction involve impairments in protein breakdown caused by a lack of key enzymes.  These symptoms have not been identified nor addressed in the current treatment and management of addiction," said Dr. Joan Fallon, Curemark founder and CEO. "The ability to identify and treat individuals with these contributory or resulting symptoms is a big step.  We believe Curemark's findings on the effects of impairments in protein breakdown on the brain will provide new understanding of the complex factors of addiction."

Curemark is currently developing a treatment for autism, CM-AT, which the U.S. Food and Drug Administration (FDA) has granted its Fast Track designation.   The FDA Fast Track program facilitates the development and expedites the review of new drugs that are intended to treat serious or life-threatening conditions, and that demonstrate the potential to meet unmet medical needs.

Curemark previously announced successful preliminary discussions with the FDA regarding the anticipated future filing of the company's New Drug Application (NDA) for CM-AT.

About Curemark LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company previously announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. To learn more about the company's innovative science, visit

Safe-Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of the Curemark products CM-AT, CM-4612 and CM-182 their potential advantages, their potential for use in treating diseases or disorders, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning the Curemark products CM-AT, CM-4612 and CM-182. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of the Curemark products CM-AT, CM-4612 and CM-182, our ability to finance our development of CM-AT, CM-4612 and CM-182 regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. K computer research results awarded ACM Gordon Bell Prize
2. BioPower Systems Awarded $5 Million from Victorian Government
3. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
4. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
5. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
6. Chinese Scientists Zhen-Yi Wang and Zhu Chen Awarded 7th Annual Szent-Gyorgyi Prize for Progress in Cancer Research
7. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
8. Sloan Research Fellowships Awarded to 126 Young Scholars
9. Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year
10. Chemring Detection Systems Awarded $500k for Strategic Research and Development
11. Leading German Researcher Awarded Elseviers 2011 Tetrahedron Prize
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):